Efficacy of bilateral repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: Results of a multicenter double-blind randomized controlled trial

Psychological Medicine

Volumn 45, Issue 6, 2015, Pages 1263-1275

  Dlabac De Lange, J J ^a   Bais, L ^a,b   Van Es, F D ^a   Visser, B G J ^a   Reinink, E ^b   Bakker, B ^b   Van Den Heuvel, E R ^a   Aleman, A ^a   Knegtering, H ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b Center for Mental Healthcare   (Netherlands)

Author keywords

Cognition; dorsolateral prefrontal cortex; insight; negative symptoms; randomized controlled trials; schizophrenia; transcranial magnetic stimulation

Indexed keywords

ADULT; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PROCEDURES; PSYCHOTIC DISORDERS; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

ADULT; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TRANSCRANIAL MAGNETIC STIMULATION; TREATMENT OUTCOME;

EID: 84925250295     PISSN: 00332917     EISSN: 14698978     Source Type: Journal    
DOI: 10.1017/S0033291714002360     Document Type: Article

References (79)

1. Aghababian V, Auquier P, Baumstarck-Barrau K, Lancon C (2011). Relationship between insight and self-reported quality of life among schizophrenic patients. L'Encephale 37, 162-171.
2. Andreasen NC (1982). Negative symptoms in schizophrenia. Definition and reliability. Archives of General Psychiatry 39, 784-788.
3. Anonymous (1944). Army Individual Test Battery: Manual of Directions and Scoring. War Department, Adjutant General's Office: Washington, DC.
4. Anonymous (1998). Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychological Medicine 28, 551-558.
5. Barr MS, Farzan F, Tran LC, Fitzgerald PB, Daskalakis ZJ (2012). A randomized controlled trial of sequentially bilateral prefrontal cortex repetitive transcranial magnetic stimulation in the treatment of negative symptoms in schizophrenia. Brain Stimulation 5, 337-346.
6. Beam W, Borckardt JJ, Reeves ST, George MS (2009). An efficient and accuratenewmethodfor locating the F3 position for prefrontal TMS applications. Brain Stimulation 2, 50-54.
7. Ben-Shachar D, Gazawi H, Riboyad-Levin J, Klein E (1999). Chronic repetitive transcranial magnetic stimulation alters β-adrenergic and 5-HT2 receptor characteristics in rat brain. Brain Research 816, 78-83.
8. Berlim MT, van den Eynde F, Tovar-Perdomo S, Daskalakis ZJ (2013). Response, remission and drop-out rates following high-frequency repetitive transcranial magnetic stimulation (rTMS) for treating major depression: a systematic review and meta-analysis of randomized, double-blind and sham-controlled trials. Psychological Medicine 44, 225-239.
9. Berman RM, Prudic J, Brakemeier EL, Olfson M, Sackeim HA (2008). Subjective evaluation of the therapeutic and cognitive effects of electroconvulsive therapy. Brain Stimulation 1, 16-26.
10. Birchwood M, Smith J, Drury V, Healy J, Macmillan F, Slade M (1994). A self-report Insight Scale for psychosis: reliability, validity and sensitivity to change. Acta Psychiatrica Scandinavica 89, 62-67.
11. Cohen E, Bernardo M, Masana J, Arrufat FJ, Navarro V, Valls-Solé J, Boget T, Barrantes N, Catarineu S, Font M, Lomeña FJ (1999). Repetitive transcranial magnetic stimulation in the treatment of chronic negative schizophrenia: a pilot study. Journal of Neurology, Neurosurgery, and Psychiatry 67, 129-130.
12. Cordes J, Thunker J, Agelink MW, Arends M, Mobascher A, Wobrock T, Schneider-Axmann T, Brinkmeyer J, Mittrach M, Regenbrecht G, Wolwer W, Winterer G, Gaebel W (2010). Effects of 10 Hz repetitive transcranial magnetic stimulation (rTMS) on clinical global impression in chronic schizophrenia. Psychiatry Research 177, 32-36.
13. Dlabac-de Lange JJ, Knegtering R, Aleman A (2010). Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: review and meta-analysis. Journal of Clinical Psychiatry 71, 411-418.
14. Ehlis AC, Herrmann MJ, Plichta MM, Fallgatter AJ (2007). Cortical activation during two verbal fluency tasks in schizophrenic patients and healthy controls as assessed by multi-channel near-infrared spectroscopy. Psychiatry Research 156, 1-13.
15. Eisenegger C, Treyer V, Fehr E, Knoch D (2008). Time-course of "off-line" prefrontal rTMS effects - a PET study. NeuroImage 42, 379-384.
16. Fenton WS, McGlashan TH (1991). Natural history of schizophrenia subtypes. II. Positive and negative symptoms and long-term course. Archives of General Psychiatry 48, 978-986.
17. Fenton WS, McGlashan TH (1994). Antecedents, symptom progression, and long-term outcome of the deficit syndrome in schizophrenia. American Journal of Psychiatry 151, 351-356.
18. Fitzgerald PB, Herring S, Hoy K, McQueen S, Segrave R, Kulkarni J, Daskalakis ZJ (2008). A study of the effectiveness of bilateral transcranial magnetic stimulation in the treatment of the negative symptoms of schizophrenia. Brain Stimulation 1, 27-32.
19. Gasquet I, Haro JM, Novick D, Edgell ET, Kennedy L, Lepine JP, SOHO Study Group (2005). Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. International Clinical Psychopharmacology 20, 199-205.
20. George MS, Post RM (2011). Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. American Journal of Psychiatry 168, 356-364.
21. Gershon AA, Dannon PN, Grunhaus L (2003). Transcranial magnetic stimulation in the treatment of depression. American Journal of Psychiatry 160, 835-845.
22. Giel R, Nienhuis FJ (1996). SCAN-2.1: Schedules for Clinical Assessment in Neuropsychiatry (in Dutch). WHO: Geneva/Groningen.
23. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE, Velligan DI (2005). Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Human Brain Mapping 25, 60-69.
24. Gonul AS, Kula M, Esel E, Tutus A, Sofuoglu S (2003). A Tc-99 m HMPAO SPECT study of regional cerebral blood flow in drug-free schizophrenic patients with deficit and non-deficit syndrome. Psychiatry Research 123, 199-205.
25. Goyal N, Nizamie SH, Desarkar P (2007). Efficacy of adjuvant high frequency repetitive transcranial magnetic stimulation on negative and positive symptoms of schizophrenia: preliminary results of a double-blind sham-controlled study. Journal of Neuropsychiatry and Clinical Neurosciences 19, 464-467.
26. Grant DA, Berg EA (1948). A behavioral analysis of degree of reinforcement and ease of shifting to new responses in a Weigl-type card-sorting problem. Journal of Experimental Psychology 38, 404-411.
27. Hajak G, Marienhagen J, Langguth B, Werner S, Binder H, Eichhammer P (2004). High-frequency repetitive transcranial magnetic stimulation in schizophrenia: a combined treatment and neuroimaging study. Psychological Medicine 34, 1157-1163.
28. Holi MM, Eronen M, Toivonen K, Toivonen P, Marttunen M, Naukkarinen H (2004). Left prefrontal repetitive transcranial magnetic stimulation in schizophrenia. Schizophrenia Bulletin 30, 429-434.
29. Ikezawa K, Iwase M, Ishii R, Azechi M, Canuet L, Ohi K, Yasuda Y, Iike N, Kurimoto R, Takahashi H, Nakahachi T, Sekiyama R, Yoshida T, Kazui H, Hashimoto R, Takeda M (2009). Impaired regional hemodynamic response in schizophrenia during multiple prefrontal activation tasks: a two-channel near-infrared spectroscopy study. Schizophrenia Research 108, 93-103.
30. Jandl M, Bittner R, Sack A, Weber B, Gunther T, Pieschl D, Kaschka WP, Maurer K (2005). Changes in negative symptoms and EEG in schizophrenic patients after repetitive transcranial magnetic stimulation (rTMS): an open-label pilot study. Journal of Neural Transmission 112, 955-967.
31. Jin Y, Kemp AS, Huang Y, Thai TM, Liu Z, Xu W, He H, Potkin SG (2012). Alpha EEG guided TMS in schizophrenia. Brain Stimulation 5, 560-568.
32. Jin Y, Potkin SG, Kemp AS, Huerta ST, Alva G, Thai TM, Carreon D, Bunney Jr WE (2006). Therapeutic effects of individualized alpha frequency transcranial magnetic stimulation (alphaTMS) on the negative symptoms of schizophrenia. Schizophrenia Bulletin 32, 556-561.
33. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S (1995). The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sciences 57, 103-107.
34. Karow A, Pajonk FG (2006). Insight and quality of life in schizophrenia: recent findings and treatment implications. Current Opinion in Psychiatry 19, 637-641.
35. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin 13, 261-276.
36. Kirkpatrick B, Fenton WS, Carpenter Jr WT, Marder SR (2006). The NIMH-MATRICS consensus statement on negative symptoms. Schizophrenia Bulletin 32, 214-219.
37. Kirkpatrick B, Strauss GP, Nguyen L, Fischer BA, Daniel DG, Cienfuegos A, Marder SR (2011). The brief negative symptom scale: psychometric properties. Schizophrenia Bulletin 37, 300-305.
38. Klein E, Kolsky Y, Puyerovsky M, Koren D, Chistyakov A, Feinsod M (1999). Right prefrontal slow repetitive transcranial magnetic stimulation in schizophrenia: a double-blind sham-controlled pilot study. Biological Psychiatry 46, 1451-1454.
39. Klemm E, Danos P, Grünwald F, Kasper S, Moller HJ, Biersack HJ (1996). Temporal lobe dysfunction and correlation of regional cerebral blood flow abnormalities with psychopathology in schizophrenia and major depression - a study with single photon emission computed tomography. Psychiatry Research 68, 1-10.
40. 11C]raclopride PET study. European Journal of Neuroscience 28, 2147-2155.
41. Kole MH, Fuchs E, Ziemann U, Paulus W, Ebert U (1999). Changes in 5-HT1A and NMDA binding sites by a single rapid transcranial magnetic stimulation procedure in rats. Brain Research 826, 309-312.
42. Lahti AC, Holcomb HH, Medoff DR, Weiler MA, Tamminga CA, Carpenter Jr WT (2001). Abnormal patterns of regional cerebral blood flow in schizophrenia with primary negative symptoms during an effortful auditory recognition task. American Journal of Psychiatry 158, 1797-1808.
43. Lako IM, Bruggeman R, Knegtering H, Wiersma D, Schoevers RA, Slooff CJ, Taxis K (2012). A systematic review of instruments to measure depressive symptoms in patients with schizophrenia. Journal of Affective Disorders 140, 38-47.
44. 2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. Journal of Clinical Psychopharmacology 33, 675-681.
45. Lane HY, Chang YC, Liu YC, Chiu CC, Tsai GE (2005). Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study. Archives of General Psychiatry 62, 1196-1204.
46. Leucht S, Pitschel-Walz G, Abraham D, Kissling W (1999). Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophrenia Research 35, 51-68.
47. Liemburg E, Castelein S, Stewart R, van der Gaag M, Aleman A, Knegtering H, Genetic Risk and Outcome of Psychosis (GROUP) Investigators (2013). Two subdomains of negative symptoms in psychotic disorders: established and confirmed in two large cohorts. Journal of Psychiatric Research 47, 718-725.
48. Lisanby SH, Gutman D, Luber B, Schroeder C, Sackeim HA (2001). Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials. Biological Psychiatry 49, 460-463.
49. Lisanby SH, Maddox JH, Prudic J, Devanand DP, Sackeim HA (2000). The effects of electroconvulsive therapy on memory of autobiographical and public events. Archives of General Psychiatry 57, 581-590.
50. Loo CK, McFarquhar TF, Mitchell PB (2008). A review of the safety of repetitive transcranial magnetic stimulation as a clinical treatment for depression. International Journal of Neuropsychopharmacology 11, 131-147.
51. Loo CK, Mitchell PB (2005). A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. Journal of Affective Disorders 88, 255-267.
52. Mennemeier M, Triggs W, Chelette K, Woods A, Kimbrell T, Dornhoffer J (2009). Sham transcranial magnetic stimulation using electrical stimulation of the scalp. Brain Stimulation 2, 168-173.
53. Milev P, Ho BC, Arndt S, Andreasen NC (2005). Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry 162, 495-506.
54. Mogg A, Purvis R, Eranti S, Contell F, Taylor JP, Nicholson T, Brown RG, McLoughlin DM (2007). Repetitive transcranial magnetic stimulation for negative symptoms of schizophrenia: a randomized controlled pilot study. Schizophrenia Research 93, 221-228.
55. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. British Journal of Psychiatry 134, 382-389.
56. Murphy BP, Chung YC, Park TW, McGorry PD (2006). Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review. Schizophrenia Research 88, 5-25.
57. Novak T, Horacek J, Mohr P, Kopecek M, Skrdlantova L, Klirova M, Rodriguez M, Spaniel F, Dockery C, Hoschl C (2006). The double-blind sham-controlled study of high-frequency rTMS (20 Hz) for negative symptoms in schizophrenia: negative results. Neuro Endocrinology Letters 27, 209-213.
58. Potkin SG, Alva G, Fleming K, Anand R, Keator D, Carreon D, Doo M, Jin Y, Wu JC, Fallon JH (2002). A PET study of the pathophysiology of negative symptoms in schizophrenia. Positron emission tomography. American Journal of Psychiatry 159, 227-237.
59. Prikryl R, Kasparek T, Skotakova S, Ustohal L, Kucerova H, Ceskova E (2007). Treatment of negative symptoms of schizophrenia using repetitive transcranial magnetic stimulation in a double-blind, randomized controlled study. Schizophrenia Research 95, 151-157.
60. Prikryl R, Ustohal L, Prikrylova Kucerova H, Kasparek T, Venclikova S, Vrzalova M, Ceskova E (2013). A detailed analysis of the effect of repetitive transcranial magnetic stimulation on negative symptoms of schizophrenia: a double-blind trial. Schizophrenia Research 149, 167-173.
61. Rey A (1958). L'examin clinique en psychologie (The examined clinical psychology). Presses universitaires de France: Paris.
62. Sabri O, Erkwoh R, Schreckenberger M, Cremerius U, Schulz G, Dickmann C, Kaiser HJ, Steinmeyer EM, Sass H, Buell U (1997). Regional cerebral blood flow and negative/positive symptoms in 24 drug-naive schizophrenics. Journal of Nuclear Medicine 38, 181-188.
63. Sachdev P, Loo C, Mitchell P, Malhi G (2005). Transcranial magnetic stimulation for the deficit syndrome of schizophrenia: a pilot investigation. Psychiatry and Clinical Neurosciences 59, 354-357.
64. Sanfilipo M, Lafargue T, Rusinek H, Arena L, Loneragan C, Lautin A, Rotrosen J, Wolkin A (2002). Cognitive performance in schizophrenia: relationship to regional brain volumes and psychiatric symptoms. Psychiatry Research 116, 1-23.
65. Schmand B, Bakker D, Saan R, Louman J (1991). The Dutch Reading Test for Adults: a measure of premorbid intelligence level. Tijdschrift voor gerontologie en geriatrie 22, 15-19.
66. Schneider AL, Schneider TL, Stark H (2008). Repetitive transcranial magnetic stimulation (rTMS) as an augmentation treatment for the negative symptoms of schizophrenia: a 4-week randomized placebo controlled study. Brain Stimulation 1, 106-111.
67. Schutter DJ, van Honk J (2006). A standardized motor threshold estimation procedure for transcranial magnetic stimulation research. Journal of ECT 22, 176-178.
68. Selemon LD, Mrzljak J, Kleinman JE, Herman MM, Goldman-Rakic PS (2003). Regional specificity in the neuropathologic substrates of schizophrenia: a morphometric analysis of Broca's area 44 and area 9. Archives of General Psychiatry 60, 69-77.
69. Shad MU, Tamminga CA, Cullum M, Haas GL, Keshavan MS (2006). Insight and frontal cortical function in schizophrenia: a review. Schizophrenia Research 86, 54-70.
70. Shi C, Yu X, Cheung EF, Shum DH, Chan RC (2014). Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis. Psychiatry Research 215, 505-513.
71. Shioiri T, Kato T, Inubushi T, Murashita J, Takahashi S (1994). Correlations of phosphomonoesters measured by phosphorus-31 magnetic resonance spectroscopy in the frontal lobes and negative symptoms in schizophrenia. Psychiatry Research 55, 223-235.
72. 11C-alphaMtrp trapping. NeuroImage 34, 1658-1664.
73. Slotema CW, Blom JD, Hoek HW, Sommer IE (2010). Should we expand the toolbox of psychiatric treatment methods to include repetitive transcranial magnetic stimulation (rTMS)? A meta-analysis of the efficacy of rTMS in psychiatric disorders. Journal of Clinical Psychiatry 71, 873-884.
74. Strafella AP, Paus T, Barrett J, Dagher A (2001). Repetitive transcranial magnetic stimulation of the human prefrontal cortex induces dopamine release in the caudate nucleus. Journal of Neuroscience 21, RC157.
75. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A (2003). Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Archives of General Psychiatry 60, 133-141.
76. van den Burg W, Saan RJ, Deelman BG (1985). 15-Woordentest. Provisional Manual (15-Word Test Provisional Manual). University Hospital: Groningen.
77. Verhage F (1983). Revised Scoring Method. University Hospital: Groningen.
78. rd edn. Psychological Corp.: San Antonio, TX.
79. Wolkin A, Sanfilipo M, Wolf AP, Angrist B, Brodie JD, Rotrosen J (1992). Negative symptoms and hypofrontality in chronic schizophrenia. Archives of General Psychiatry 49, 959-965.